Invion (FRA:7C8) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invion Net Margin %?

Invion FRA:7C8 Net Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 962 Drug Manufacturers companies, Invion ranks worse than 103950% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Invion's Net Income for the six months ended in Dec. 2025 was €-2.02 Mil. Invion's Revenue for the six months ended in Dec. 2025 was €0.00 Mil. Therefore, Invion's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Invion's Net Margin % or its related term are showing as below:


FRA:7C8's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.56
* Ranked among companies with meaningful Net Margin % only.

Invion  (FRA:7C8) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Invion Net Margin % Related Terms

Invion Net Margin % Historical Data

* Premium members only.

The historical data trend for Invion's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Net Margin % Chart

Invion Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63.62 -68.10 -39.32 -152.35 0.00

Invion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.02 -335.29 0.00 0.00 0.00

FRA:7C8 vs ZTS, UTHR: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invion Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's Net Margin % distribution charts can be found below:

* The bar in red indicates where Invion's Net Margin % falls into.


Invion Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Invion's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-4.972/0
= %

Invion's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.023/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Invion (FRA:7C8) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Invion and its competitors. According to the industry distribution chart, Invion ranks #999999 out of 962 companies in the Drug Manufacturers industry.
Is Invion's Net Margin % too high?
Invion's current Net Margin % is 0.00%. Based on the distribution chart, Invion ranks #999999 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Invion's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Invion ranks #999999 out of 962 companies for Net Margin %. This places Invion in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Invion and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invion's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Based on GuruFocus' analysis, Invion (FRA:7C8) is currently considered Possible Value Trap. The stock's GF Value™ is €0.08, compared to a current price of €0.02 — trading 73.8% below its estimated fair value. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Invion (FRA:7C8), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invion Business Description

Other Exchanges IVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.